SCHEMBL8107068

SCHEMBL8107068

C[C@H]1CC[C@]1(C(=O)O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 1/20 0.46
CYP2D6 P10635 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
ALOX15 P16050 1/20 0.43
MAOB P27338 1/20 0.41
OPRM1 P35372 1/20 0.40
OPRL1 P41146 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12020309 1.00 AKR1C1 (0.46) AKR1C1CYP2D6LMNAHTTALOX15
SCHEMBL8105095 1.00 AKR1C1 (0.46) AKR1C1CYP2D6LMNAHTTALOX15
SCHEMBL9330568 0.89 AKR1C1 (0.47) AKR1C1CYP2D6LMNAHTTALOX15
SCHEMBL9330906 0.87 AKR1C1 (0.50) AKR1C1CYP2D6LMNAHTTALOX15
SCHEMBL5437376 0.84 MAOB (0.47) AKR1C1CYP2D6MAOB
SCHEMBL11487632 0.84 CYP2D6 (0.49) CYP2D6
SCHEMBL4945226 0.84 CCR2 (0.43)
SCHEMBL11480274 0.84 CYP2D6 (0.36) CYP2D6LMNAHTT
SCHEMBL28577843 0.79 AKR1C1 (0.44) AKR1C1LMNAHTTALOX15MAOB
SCHEMBL21119266 0.78 OPRM1 (0.42) AKR1C1CYP2D6ALOX15MAOBOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6124354-A TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME PHARMACIA & UPJOHN AB (SE) 2000-09-26 US disclosed
EP-0923536-A1 ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION Pharmacia & Upjohn Aktiebolag (SE) 1999-06-23 EP disclosed
WO-1998004517-A1 ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION PHARMACIA & UPJOHN AB (SE) 1998-02-05 WO disclosed